Business
Medical Marijuana, Inc. Investment Company AXIM® Biotechnologies Receives New U.S. Patent Issuance for Chewing Gum Comprising Cannabinoids and Nicotine
Medical Marijuana, Inc. Investment Company AXIM® Biotechnologies Receives New U.S. Patent Issuance for Chewing Gum Comprising Cannabinoids and Nicotine.
About this update from Axim Biotechnologies, Inc.
[{"type":"text","content":"\n\n\n\nMedical Marijuana, Inc. Investment Company AXIM® Biotechnologies Receives New U.S. Patent Issuance for Chewing Gum Comprising Cannabinoids and Nicotine\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nMedical Marijuana, Inc. Investment Company AXIM® Biotechnologies Receives New U.S. Patent Issuance for Chewing Gum Comprising Cannabinoids and Nicotine\nPR Newswire\nSAN DIEGO, April 8, 2020\n\n\n\nSAN DIEGO, April 8, 2020 /PRNewswire/ -- Medical Marijuana, Inc. (OTC: MJNA) (the \"Company\"), the first-ever publicly traded cannabis company in the United States that launched the world's first-ever cannabis-derived nutraceutical products, brands and supply chain, announced today that its investment company AXIM® Biotechnologies, Inc. (OTCQB: AXIM) (\"AXIM® Biotech\" or \"AXIM\") has been issued a Notice of Allowance for a patent from the United States Patent and Trademark Office (USPTO) on a method to use a chewing gum composition of cannabinoids and nicotine according to a patented formula to treat or alleviate tobacco smoking.\n\"As proven by the estimated $21.8 billion smoking cessation market, there are many people across the globe looking to quit smoking,\" said Medical Marijuana, Inc. CEO Dr. Stuart Titus. \"AXIM now has the opportunity to potentially provide consumers with a unique and effective option to help them do so.\"\nThe USPTO granted this allowance from AXIM's patent application 15/494,514 filed on April 23, 2017. AXIM's robust intellectual property pipeline now includes nine patents, one newly issued allowance and 13 patents pending. Most notably, AXIM holds a patent for chewing gum as a delivery mechanism for all cannabinoids, including cannabidiol (CBD).\n\"AXIM is proud to have secured many cannabinoid-based patents over the past year and become an industry leader in cannabis intellectual property,\" said AXIM® Biotech CEO John W. Huemoeller II. \"We're looking forward to continuing to develop many proprietary supplements to promote wellness for all of our customers.\"\nTo learn more about Medical Ma...